Candidate NameCand | PreclinicalPre | Phase 1Ph 1 | Phase 2Ph 2 | Phase 3Ph 3 | CollaboratorsCollab | | |
---|
Monotherapy |
ZN-c3: Wee1 InhibitorUterine Serous Carcinoma* Uterine Serous Carcinoma+USC+ |
Biomarker-Driven*Biomarker* |
|
Combination |
ZN-c3: Wee1 InhibitorOsteosarcoma (+ gemcitabine)* Osteosarcoma (+ gemcitabine)*Osteosarcoma |
Ovarian Cancer (+ niraparib) Ovarian Cancer (+ niraparib)Ov Cancer |
Ovarian Cancer (+ chemo)Ov Cancer |
| |
---|
Monotherapy |
ZN-d5: BCL-2 InhibitorAL Amyloidosis* AL Amyloidosis*AL Amyloidosis* |
AML + Non-Hodgkin’s Lymphoma AML + Non-Hodgkin’s LymphomaAML + Non-Hodgkin’s Lymphoma |
Combination |
AML (+ ZN-c3)AML (+ ZN-c3) |
| |
---|
Monotherapy |
ZN-c5: Oral SERD1Breast Cancer |
| |
---|
Monotherapy |
ZN-e4: EGFR Inhibitor1NSCLC |
| |
---|
Monotherapy |
Solid Tumors and Hematology MalignanciesSolid Tumors and Heme Malignancies |
+ Registrational trial with FDA Fast Track designation
* Potentially registrational trial
1 Zentalis will discontinue the clinical development of ZN-c5 and ZN-e4 following completion of its existing clinical trials, which are closed to accrual, in these two programs.
Learn More